The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | MT-5111: immunotoxin in HER2+ solid tumours

Name: MT-5111: immunotoxin in HER2+ solid tumours
Uploaded: 2020-07-08T00:00:00Z
Duration: 59 s
Description: Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, outlines results from a Phase I study evaluating MT-5111, a novel immunotoxin, in HER-2 positive solid tumours. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Zev Wainberg • 8 Jul 2020

ESMO WCGIC 2020

Gastrointestinal Cancer General MT-5111

Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, outlines results from a Phase I study evaluating MT-5111, a novel immunotoxin, in HER-2 positive solid tumours. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).